Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Antibody capable of being specifically combined with GLP-1R and fusion protein of antibody and GLP-1

A GLP-1R, GLP-1 technology, applied in the field of antibodies, can solve the problems of poor therapeutic effect and short half-life

Active Publication Date: 2015-02-25
GMAX BIOPHARM
View PDF8 Cites 15 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, GLP-1 has a short half-life in the body, and the therapeutic effect is not good

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Antibody capable of being specifically combined with GLP-1R and fusion protein of antibody and GLP-1
  • Antibody capable of being specifically combined with GLP-1R and fusion protein of antibody and GLP-1
  • Antibody capable of being specifically combined with GLP-1R and fusion protein of antibody and GLP-1

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0098] The technical solutions of the present invention will be further specifically described below through specific embodiments and in conjunction with the accompanying drawings.

[0099] In the present invention, unless otherwise specified, the raw materials and equipment used can be purchased from the market or commonly used in this field. The methods in the following examples, unless otherwise specified, are conventional methods in the art.

[0100] Step 1: Construction of stable antigen cell strains for immunization

[0101] Inoculate CHO-DHFR cells into a 6-well plate, and transfect the pYS plasmid containing the hGLP-1R gene (see SEQ ID NO: 113 for the nucleotide sequence, and SEQ ID NO: 114 for the amino acid sequence) in a 6-well plate after culturing for 24 hours Change the culture medium before transfection, and transfect according to the transfection conditions of Lipofectamine 2000 recommended by Invitrogen. After 48 hours, change to the complete medium contain...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Disclosed in the present invention is an antibody specifically binding to GLP-1R and a fusion protein thereof with GLP-1. The fusion proteins can effectively bind to a human GLP-1R receptor and activate a receptor signalling channel, thus are useful for treating diabetes, excessive weight, obesity and related disorders thereof.

Description

technical field [0001] The invention relates to the technical field of antibodies, in particular to an antibody capable of specifically binding to GLP-1R and a fusion protein thereof with GLP-1. Background technique [0002] The typical symptoms of type II diabetes include the following three aspects: 1) Peripheral insulin resistance, mainly the decreased stress of bones and muscles to insulin, resulting in the influence of glucose output to these tissues (Kahn and Goldfine, J Diabetes Complication (1993 ) 7:92-105; Weyer et al., J Clin Invest. (1999) 104:787-794); 2) Excessive hepatic glucose production, decreased hepatic cell regulation stress to insulin (Kahn and Goldfine, J Diabetes Complication. (1993) 7:92-105; Lam et al., Am J Physiol Endocrinol Metab. (2009) 11:375-378) and hypersecretion of glucagon (Unger and Orci, Arch Intern Med. (1977) 137:482 -491); 3) Pancreatic beta cell dysregulation, in the early stage of the disease, the proliferation of beta cells and in...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K16/28C07K19/00C12N15/62A61K38/26A61K47/48A61P3/10
CPCC07K2317/75C07K14/605C07K2319/00C07K16/2869A61K38/00A61P43/00A61P3/10A61K2039/505A61K38/26A61K39/395A61K47/6811A61P3/08C07K16/18C07K16/28C07K19/00C07K2317/24C07K2317/34C07K2317/565C07K2319/31C12N15/09C12N15/62C12N15/63
Inventor 张成景书谦章华汪笑峰药晨江
Owner GMAX BIOPHARM
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com